Aisling Capital Partners III LLC
CIK 0001532635 Name as filed on the most recent filing
Filed as Aisling Capital Partners III LLC (20)
22 transaction lines · from 20 filings · filed 2011-10-25 to 2018-07-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Loxo Oncology, Inc. 9 filings
- ISSUER Syros Pharmaceuticals, Inc. 1 filings
- ISSUER T2 Biosystems, Inc. 2 filings
- ISSUER Versartis, Inc. 2 filings
- ISSUER Agile Therapeutics Inc 1 filings
- ISSUER Transenterix Inc. 1 filings
- ISSUER Durata Therapeutics, Inc. 2 filings
- ISSUER Zeltiq Aesthetics Inc 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2018-07-10 |
Loxo Oncology, Inc. LOXO |
S, Open-market sale | 1,400,000 disposed | 179.43 | 251,202,000.00 | Form 4, filing 0000899243-18-019810 | |
| 2017-12-19 |
Loxo Oncology, Inc. LOXO |
S, Open-market sale | 250,000 disposed | 80.50 | 20,125,000.00 | Form 4, filing 0000950142-17-002235 | |
| 2017-11-22 |
Loxo Oncology, Inc. LOXO |
S, Open-market sale | 500,000 disposed | 75.00 | 37,500,000.00 | Form 4, filing 0000950142-17-002107 | |
| 2017-01-10 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 160,000 acquired | 31.00 | 4,960,000.00 | Form 4, filing 0000950142-17-000108 | |
| 2016-07-06 |
Syros Pharmaceuticals, Inc. SYRS |
P, Open-market purchase | 400,000 acquired | 12.50 | 5,000,000.00 | Form 4, filing 0000950142-16-004060 | |
| 2016-05-17 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 232,558 acquired | 21.50 | 4,999,997.00 | Form 4, filing 0000950142-16-003763 | |
| 2015-12-11 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 200 acquired | 27.50 | 5,500.00 | Form 4, filing 0000950142-15-002621 | |
| 2015-12-09 |
T2 Biosystems, Inc. TTOO |
P, Open-market purchase | 307,692 acquired | 9.75 | 2,999,997.00 | Form 4, filing 0000950142-15-002576 | |
| 2015-11-17 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 265,000 acquired | 26.50 | 7,022,500.00 | Form 4, filing 0000950142-15-002461 | |
| 2015-11-13 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 1,955 acquired | 27.47 | 53,704.24 | Form 4, filing 0000950142-15-002434 | |
| 2015-11-12 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 76,714 acquired | 27.65 | 2,121,318.54 | Form 4, filing 0000950142-15-002434 | |
| 2015-01-27 |
Versartis, Inc. VSAR |
P, Open-market purchase | 145,000 acquired | 17.25 | 2,501,250.00 | Form 4, filing 0000950142-15-000194 | |
| 2015-01-23 |
Agile Therapeutics Inc AGRX |
P, Open-market purchase | 811,966 acquired | 5.85 | 4,750,001.10 | Form 4, filing 0000950142-15-000157 | |
| 2014-08-12 |
T2 Biosystems, Inc. TTOO |
P, Open-market purchase | 454,545 acquired | 11.00 | 4,999,995.00 | Form 4, filing 0001104659-14-061090 | |
| 2014-08-06 |
Loxo Oncology, Inc. LOXO |
P, Open-market purchase | 413,077 acquired | 13.00 | 5,370,001.00 | Form 4, filing 0001140361-14-031039 | |
| 2014-04-21 |
Transenterix Inc. TRXC |
P, Open-market purchase | 1,037,767 acquired | 4.00 | 4,151,068.00 | Form 4, filing 0000950142-14-000941 | |
| 2014-03-26 |
Versartis, Inc. VSAR |
P, Open-market purchase | 60,000 acquired | 21.00 | 1,260,000.00 | Form 4, filing 0001209191-14-023549 | |
| 2014-03-21 |
Durata Therapeutics, Inc. DRTX |
S, Open-market sale | 2,649 disposed | 15.57 | 41,255.00 | Form 4, filing 0000950142-14-000705 | |
| 2014-03-20 |
Durata Therapeutics, Inc. DRTX |
S, Open-market sale | 98,000 disposed | 15.74 | 1,542,588.60 | Form 4, filing 0000950142-14-000705 | |
| 2013-11-14 |
Zeltiq Aesthetics Inc ZLTQ |
S, Open-market sale | 575,000 disposed | 12.22 | 7,026,500.00 | Form 4, filing 0000950142-13-002267 | |
| 2012-07-24 |
Durata Therapeutics, Inc. DRTX |
P, Open-market purchase | 1,111,111 acquired | 9.00 | 9,999,999.00 | Form 4, filing 0000950142-12-001608 | |
| 2011-10-24 |
Zeltiq Aesthetics Inc ZLTQ |
P, Open-market purchase | 769,231 acquired | 13.00 | 10,000,003.00 | Form 4, filing 0001181431-11-053467 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Aisling Capital Partners III LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001532635
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6